Price
No data yet.
Social Signal Score
30
5d
30
1 mentions
—
30d
30
1 mentions
—
60d
30
1 mentions
—
90d
30
1 mentions
—
news: 1
Revenue
$276.00M+33.33%Mar 2022Jun 2023
Company Profile
- CEO
- Mark Crossley
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 1,000
- Beta
- -0.06
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 2.80
Financials
Revenue
$276.00M+33.3%Net Income
$39.00M-4.9%EBITDA
$86.00M+45.8%Free Cash Flow
$-20.00MEPS (diluted)
$0.28+0.0%Shares Outstanding (diluted)
140.99M-3.6%Operating Expenses
$157.00MR&DSG&A
Cash & Debt
$689.00MCash & investmentsTotal debt
Return of Capital
$0.00BuybacksDividends
Dividend per Share
$0.47Quote
Day Range
$21.85 – $21.85
52-Week Range
$14.76 – $75.65
Volume
$8.1K
Market Cap
$3.01B
50-Day Avg
$24.24
200-Day Avg
$21.39
Prev Close
$21.85
Open
$21.65
Valuation & Ratios
P/E Ratio
-62.78
EPS
$-0.38
P/B Ratio
61.60
P/S Ratio
3.49
Debt/Equity
5.43
Current Ratio
1.24
Dividend Yield
+0.0%
Gross Margin
+82.4%
Returns & Efficiency
Return on Equity
-103.9%
Return on Assets
-3.0%
FCF Yield
-0.3%
EV/EBITDA
-51.86
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2022 | $901.00M | $-53.00M | $-0.36 |
| 2021 | $791.00M | $205.00M | $1.41 |
| 2020 | $647.00M | $-148.00M | $-0.96 |
| 2019 | $785.00M | $134.00M | $0.90 |
Valuation
INVVYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80Aug 21Aug 21
Social Signal Score
30
5d
30
1 mentions
—
30d
30
1 mentions
—
60d
30
1 mentions
—
90d
30
1 mentions
—
news: 1
Mentions (1)
- Newszacks.com·6h ago·Negative
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.
View source ↗